127 related articles for article (PubMed ID: 38858522)
21. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
[TBL] [Abstract][Full Text] [Related]
22. Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate.
Retz W; Rösler M; Ose C; Scherag A; Alm B; Philipsen A; Fischer R; Ammer R;
World J Biol Psychiatry; 2012 Jan; 13(1):48-59. PubMed ID: 21155632
[TBL] [Abstract][Full Text] [Related]
23. The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial.
Mitchell GK; Hardy JR; Nikles CJ; Carmont SA; Senior HE; Schluter PJ; Good P; Currow DC
J Pain Symptom Manage; 2015 Sep; 50(3):289-96. PubMed ID: 25896104
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Multilayer, Extended-Release Methylphenidate (PRC-063) in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder: A Laboratory Classroom Study.
Childress AC; Brams MN; Cutler AJ; Donnelly GAE; Bhaskar S
J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):580-589. PubMed ID: 33090921
[No Abstract] [Full Text] [Related]
25. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
Efron D; Jarman F; Barker M
Pediatrics; 1997 Oct; 100(4):662-6. PubMed ID: 9310521
[TBL] [Abstract][Full Text] [Related]
26. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
[TBL] [Abstract][Full Text] [Related]
27. A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder.
Kollins SH; Braeckman R; Guenther S; Barrett AC; Mickle TC; Oh C; Marraffino A; Cutler AJ; Brams MN
J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):597-609. PubMed ID: 34714120
[No Abstract] [Full Text] [Related]
28. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
29. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.
Lanctôt KL; Scherer RW; Li A; Vieira D; Coulibaly H; Rosenberg PB; Herrmann N; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer JE
Am J Geriatr Psychiatry; 2021 Jan; 29(1):81-89. PubMed ID: 32565008
[TBL] [Abstract][Full Text] [Related]
30. Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study.
Kis B; Lücke C; Abdel-Hamid M; Heßmann P; Graf E; Berger M; Matthies S; Borel P; Sobanski E; Alm B; Rösler M; Retz W; Jacob C; Colla M; Huss M; Jans T; van Elst LT; Müller HHO; Philipsen A
Pharmacopsychiatry; 2020 Nov; 53(6):263-271. PubMed ID: 33017854
[TBL] [Abstract][Full Text] [Related]
31. Improvement of neuronal integrity with methylphenidate treatment for apathy in Alzheimer's disease.
Padala PR; Padala KP; Samant RS; James GA
Int Psychogeriatr; 2020 Apr; 32(4):539-540. PubMed ID: 32019622
[No Abstract] [Full Text] [Related]
32. Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Wigal SB; Childress A; Berry SA; Belden H; Walters F; Chappell P; Sherman N; Orazem J; Palumbo D
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):690-699. PubMed ID: 28557548
[TBL] [Abstract][Full Text] [Related]
33. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
[TBL] [Abstract][Full Text] [Related]
34. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.
Lanctôt KL; Rivet L; Tumati S; Perin J; Sankhe K; Vieira D; Mintzer J; Rosenberg PB; Shade D; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey AI; Padala KP; Herrmann N
Am J Geriatr Psychiatry; 2023 Dec; 31(12):1077-1087. PubMed ID: 37385898
[TBL] [Abstract][Full Text] [Related]
36. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
37. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.
Rösler M; Fischer R; Ammer R; Ose C; Retz W
Eur Arch Psychiatry Clin Neurosci; 2009 Mar; 259(2):120-9. PubMed ID: 19165529
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]